Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide

Br J Haematol. 2003 Nov;123(4):747-8; author reply 748. doi: 10.1046/j.1365-2141.2003.04677.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Biomarkers / blood
  • Disease Progression
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Membrane Proteins / blood*
  • Multiple Myeloma / blood*
  • Prospective Studies
  • Thalidomide / therapeutic use*

Substances

  • Biomarkers
  • Immunosuppressive Agents
  • Membrane Proteins
  • Thalidomide